Post hoc analysis of two trials (246 Japanese patients with rheumatoid arthritis on ozoralizumab): the higher baseline disease activity in those with large joint involvement was no longer seen from day 3 onwards; week-24 joint damage progression was similar.
Secondary analysisn = 246
Ebina et al. Efficacy of ozoralizumab in rheumatoid arthritis patients with large joint involvement: a post hoc analysis of OHZORA and NATSUZORA trials